Seqvera Ltd. is a Finland-based SME specializing in the development and application of testing and optimization of medical devices compliant to 2017/745, in vitro medical devices compliant to 2017/746, health technology assessment, as well as R&D in bioprinting, ATMP, SoHO and combined products, complemented with proprietary data analysis and digital enhancements and related consulting services.
Seqvera has several granted patents related to medical devices examination such as BEST (Biomaterials Enhanced Simulation Testing) and SIT (Systemic Injectability Testing), with other pending patents.
The company is also actively involved in EU projects and programs related to women's health, pregnancy safety, perinatal derivatives and other innovative solutions.
Seqvera is the official promoter of the medical devices and pharma policy advice in the European Parliament.
Department of Molecular Medicine
(IMM - Institut for Molekylær Medicin)
Faculty of Health
Department of Biochemistry and Molecular Biology
Faculty of Natural Sciences
The University of Southern Denmark (SDU - Syddansk Universitet) is a prominent educational institution in Denmark.
SDU was established in 1998 through the merging of the Odense University, the Southern Denmark School of Business, the Engineering and the South Jutland University Centre, and the Library of Southern Denmark.
SDU has five faculties and about 32,000 students, more than 15% of whom come from abroad. The more than 4,000 employees are divided between the main campus in Odense and regional campuses in Slagelse, Kolding, Esbjerg, Sønderborg and Copenhagen.
SDU offers a wide range of higher education programs, including Bachelor, Master, and PhD degree programs, and it is known for its academic excellence, and it is considered one of the top public universities in Denmark.
Principal investigators from two departments at the SDU integrate CARE-IN-HEALTH.
The first one is at the Department of Molecular Medicine (IMM - Institut for Molekylær Medicin), at the Faculty of Health, which is a vital part of the university's academic and research activities. IMM research focuses on understanding the molecular and cellular aspects of medicine, with a strong emphasis on deciphering the underlying mechanisms of major diseases and the development of innovative medical solutions.
The second one is at the Department of Biochemistry and Molecular Biology (BMB), at the Faculty of Natural Sciences, which focuses its research on basic molecular and biochemical processes to provide insights into the mechanisms of disease development, for instance in diabetes, cancer, neurodegenerative disorders and pathogenic bacterial infections.
Qlucore was founded in early 2007 and began as a collaborative research project at Lund University, Sweden, with researchers in the Departments of Mathematics and Clinical Genetics.
The Qlucore software provides a tool for analyses of high-dimensional data sets that is extremely fast and allows the user to explore and analyze data interactively and in real time with the use of a normal computer. The generic software engine has an user interface and an user model optimized for fast and easy use. For many types of data, it only requires a very limited number of key presses or mouse clicks to generate the first plot with relevant content.
Precision and companion diagnostics are going to have a fundamental impact on healthcare and in 2020 a major step was taken by adding a new product line for diagnostics including two products Qlucore Insights and Qlucore Diagnostics. These are based on a diagnostics software platform for multi-omics companion and precision diagnostics. AI-powered, disease-specific machine learning-based classifier models are combined with patient-friendly visualizations in an easy to use and cost-effective software solution that integrates with a wide range of data-generating techniques and instruments.
Valle MONTALVO ROMERAL
Founded in 2000, Inserm Transfert SA is the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), dedicated to technology transfer (from invention disclosure to industrial partnership). Inserm Transfert runs a comprehensive set of technology transfer activities from classical value chain activities to unique solutions:
- Scouting & Intellectual property management, with a philosophy of giving a chance to all innovations (portfolio of 2190 patent families in 2021)
- Early development & Proof-of concept support for therapeutics and diagnostics (biomarkers), with a philosophy of maximum consolidation of the earliest phases, with more than 21 M€ since 2009 with the objective to create value. In 2021, 250 projects were detected and about 500 contracts and licences were signed.
- Setting up public multi-private partnerships on cohorts, databases, biobanks & public health management
- Collaborative Research Funding: setting up proposals and managing collaborative research projects (FP7, H2020, IMI, national programmes, etc.)